STOCKHOLM, Dec. 17, 2019 /PRNewswire/ -- An
Extraordinary General Meeting in Oncopeptides AB (publ) (ONCO) was
held today, at Tändstickspalatset in Stockholm. At the Extraordinary General
Meeting, the following principal resolutions were passed.
- It was resolved, in accordance with the Board of Directors'
proposal, to issue not more than 2,200,000 warrants in order to
ensure delivery of shares under the incentive program Co-worker
LTIP 2019, adopted by the Annual General Meeting 2019.
- It was resolved, in accordance with the Nomination Committee's
proposal, to issue not more than 23,491 warrants in order to ensure
delivery of shares under the incentive program Board LTIP 2019,
adopted by the Annual General Meeting 2019.
- It was resolved, in accordance with the Board of Directors'
proposal, to authorize the Board of Directors to, until the next
Annual General Meeting, on one or more occasions, decide upon
issuances of new shares and/or issues of convertibles. New issues
of shares and/or issues of convertibles may occur with or without
preferential rights for shareholders of the company and may be made
either in cash and/or by way of set-off or contribution in kind or
otherwise on terms. The purpose of the authorization is to increase
the financial flexibility of the company and the acting scope of
the Board of Directors. Should the Board of Directors resolve
on an issue with deviation from the shareholders' preferential
rights, the reason for this must be to finance an acquisition of
operations or, alternatively, to procure capital to finance project
development. Upon such deviation from the shareholders'
preferential rights, the new issue shall be made at market terms
and conditions. The number of shares issued under the
authorization, or the number of shares created in connection with
conversion of convertibles, may not correspond to a dilution of
more than 20 per cent of the total number of shares outstanding at
the Extraordinary General Meeting's resolution on the proposed
authorization, after full exercise of the authorization. The
authorization replaces the authorization resolved upon at the
Annual General Meeting 2019.
About Oncopeptides
Oncopeptides is a pharmaceutical company focused on the
development of targeted therapies for difficult-to-treat
hematological diseases. The company is focusing on the development
of the lead product candidate melflufen, a novel peptide-drug
conjugate that rapidly delivers a cytotoxic payload into tumor
cells. Melflufen is in development as a new treatment for the
hematological cancer multiple myeloma and is currently being tested
in multiple clinical studies including the pivotal phase 2 HORIZON
study and the ongoing phase 3 OCEAN study. Oncopeptides'
headquarters is in Stockholm,
Sweden, and the company is listed in the Mid Cap segment on
Nasdaq Stockholm with the ticker ONCO.
For more information please visit
www.oncopeptides.com.
For further information, please contact:
Jakob Lindberg, CEO of
Oncopeptides
E-mail: jakob.lindberg@oncopeptides.com
Telephone: +46-8-615-2040
Rein Piir, Head of Investor Relations at Oncopeptides
E-mail: rein.piir@oncopeptides.com
Cell phone: +46-70-853-7292
The above information was released for public disclosure on
17 December, 2019 at 04.15 p.m. (CET).
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/oncopeptides-ab/r/bulletin-from-the-extraordinary-general-meeting-in-oncopeptides-ab--publ-,c2993167
The following files are available for download:
https://mb.cision.com/Main/15404/2993167/1163398.pdf
|
EGM Bulletin
Oncopeptides AB Dec17, 2019
|
View original
content:http://www.prnewswire.com/news-releases/bulletin-from-the-extraordinary-general-meeting-in-oncopeptides-ab-publ-300976163.html
SOURCE Oncopeptides AB